Research article

An evaluation of concordance between head and neck advanced practice radiation therapist and radiation oncologists in toxicity assessment for nasopharyngeal carcinoma patients

S.Y. Sin a,b,c, Melvin L.K. Chua a,b, Sharon M.M. Wong a,c,d, K. Sommat a,b, X.Y. Lin a, Y.Y. Ng a, Y.L. Soong a,b

a Division of Radiation Oncology, National Cancer Centre Singapore, Singapore
b Duke-National University of Singapore, Graduate Medical School, Singapore
c College of Allied Health-SingHealth Academy, Singapore
d Singapore Institute of Technology, Singapore

ARTICLE INFO

Keywords:
Advanced practice radiation therapist
Concordance
Toxicity assessment
NPC
Radiotherapy side effects
Head and neck APRT

ABSTRACT

Background: Weekly toxicity assessments for patients undergoing head and neck (HN) radiotherapy are essential to ensure that acute side effects are appropriately managed in order for patients to complete their treatment in a safe and timely manner. The incorporation of Advanced Practice Radiation Therapist (APRT) led treatment review has been reported for various subsites, but there is currently a lack of published literature regarding this role for patients with HN cancer. The purpose of this study is to assess the concordance of toxicity assessments performed during weekly radiotherapy treatment reviews for patients undergoing HN radiotherapy between the HN APRT and Radiation Oncologist (RO).

Methods: Twenty-three patients with nasopharyngeal cancer (NPC) under the care of 3 ROs were recruited from June to December 2018; weekly assessments were independently performed by HN APRT and ROs. The HN toxicity assessment was graded according to the Common Terminology Criteria for Advanced Events v4.0. Both assessors were blinded to each other’s assessments. The percentage agreement of concordance and agreement level were interpreted by Cohen’s Kappa statistic (κ), with the ROs’ assessments deemed as the ‘gold standard’. The overall concordance for all graded toxicity assessments between HN APRT and ROs was 78.4%. Xerostomia, dysgeusia, pharyngeal pain and dermatitis assessment were evaluated as ‘Good’ with agreement ranging from κ = 0.608–0.640 between the HN APRT and ROs while dysphagia scored an ‘Almost Perfect’ agreement of κ = 0.834. ‘Moderate’ agreement between the HN APRT and ROs was observed for oral pain and mucositis assessment. A scoring discrepancy of 1 and 2 grades was observed in 21.2% and 0.4% for these two toxicities.

Conclusion: There was high concordance in scoring of acute toxicity between the HN APRT and ROs. The results support the continuing involvement of HN APRT in weekly assessments for NPC patients.

Introduction

The nasopharynx is a cuboidal space bounded by the nasal cavity (anteriorly), the soft palate (inferiorly), the skull base (superiorly), posterior pharyngeal wall (posteriorly) and the medial pterygoid plates (laterally), with the anterior-posterior diameter of 2 cm and the height of 4 cm [1]. Despite its small size, nasopharyngeal cancers (NPC) which arises from here, is the most common head and neck (HN) cancer in Singapore [2,3]. This distinct HN malignancy has an unbalanced geographical distribution with 81% of cases arising in Asia, 9% in Northern Africa and the remaining worldwide [4,5]. In the endemic region, the most common histology is non-keratinizing undifferentiated carcinoma, which is highly associated with Epstein-Barr virus (EBV) with evidence of infection seen in more than 95% of NPC [4,5]. Due to its anatomical location and radiosensitivity, radiotherapy (RT), with or without chemotherapy, is the primary modality for radical treatment.

* Corresponding author.
E-mail address: sin.sze.yarn@nccs.com.sg (S.Y. Sin).

https://doi.org/10.1016/j.tipsro.2021.08.001
Received 11 May 2021; Received in revised form 24 July 2021; Accepted 5 August 2021
Available online 4 September 2021

© 2021 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy & Oncology. This is an open access article under the
Severe radiation induced toxicities. Oral mucositis is a common side effect of HN irradiation and the incidence is increased in patients that require concurrent chemoradiotherapy (CCRT) [2, 7, 8].

Similar to other HN squamous cell cancers, NPC is a fast-proliferating tumour and hence, prolonged overall treatment time is detrimental for local control and overall survival for NPC patients [9]. Poor management of acute side effects is a common, but potentially avoidable reason. A dose of 70 Gray in 33–35 fractions over 6.5–7 weeks is required to treat NPC. Advanced RT techniques such as Intensity-Modulated Radiation Therapy (IMRT) is commonly used to minimize dose to adjacent critical structures such as the parotid glands, tongue and constrictor muscles [6]. Despite this, NPC patients typically experience severe radiation induced toxicities. Oral mucositis is a common side effect of HN irradiation and the incidence is increased in patients that require concurrent chemoradiotherapy (CCRT) [2, 7, 8].

In 2012, the Advanced Practice Radiation Therapist (APRT) specializing in HN cancer was piloted in National Cancer Centre Singapore (NCCS), with the endeavor to provide seamless care for patients having HN radiotherapy and to elevate the professional profile of radiation therapists [12–14]. This was also supported from ROs in our centre for trained APRT led treatment reviews, assessment of toxicities and reinforce nutritional recommendation made by the medical team, consistent with findings performed by Shi et al. [15]. The HN APRT underwent advanced site-specific education and 3 years of intensive clinical training by 3 HN ROs. The clinical training included understanding patient history and initial diagnosis, management of various HN sub-sites and radiation induced toxicities of HN treatment. The HN APRT was responsible for leading and developing key departmental HN initiatives through active involvement with the multi-disciplinary care team. With numerous integrated holistic training and comprehensive competency assessments, the role of the HN APRT was successfully expanded to include reviewing patients independently on behalf of ROs, subsequently reducing the overall waiting time for patients. Moreover, it helped to lessen the ROs’ workload, thereby permitting them to focus more on complicated cases, treatment planning and research [12].

The contribution of HN APRT in toxicity assessment for NPC radiotherapy patients was established in 2017 with the key intention to closely monitor patients’ radiation induced toxicity and psychosocial issues pertaining to their treatment. To further support and validate this role delegation, the concordance of toxicity assessment between HN APRT and ROs in patients with NPC patients was conducted to show that HN APRT’s toxicity assessment is comparable to ROs.

Methods

This study was conducted with twenty-three NPC patients under the care of 3 ROs from June to December 2018. All patients were treated with either CCRT or radiotherapy alone with a dose of 70 Gray in 33 fractions over 6.5 weeks. Weekly assessments were performed independently by both the HN APRT and RO-in-charge. To benchmark the best observation of assessment, the RO’s grading was deemed as ‘gold standard’.

Radiation induced toxicities that are commonly observed in HN radiotherapy were shortlisted from the Common Terminology Criteria for Advanced Events (CTCAE) v4.0. A form adapted from the CTCAE v4.0 was included in the departmental Head and Neck Radiation Therapy Protocol and standardized for the use of patient assessment during RT. The evaluated HN toxicities included xerostomia, oral pain, mucositis, dysgeusia, dysphagia, pharyngolaryngeal pain and dermatitis. The APRT assessed patients every Monday, whereas the ROs assessed patients on Mondays, Thursdays or Fridays depending on their work schedule.

Both assessors evaluated the symptoms of radiation induced toxicities using the method described in Table 1. The HN APRT’s assessment was graded according patients to the CTCAE v4.0 form (Fig. 1). The ROs’ chart documentation was translated by the HN APRT and verified by the ROs to the CTCAE form for comparison. Hoarseness of voice was not included in this study as it is not a common side effect observed among the NPC patients undergoing radiotherapy as compared to other HN cancers.

The concordance rate and agreement level were interpreted by Cohen’s Kappa statistic, where it was used to measure the inter assessor reliability. According to Landis and Koch’s classification method, the agreement levels of Kappa results are interpreted as follows: value $<0$ indicates No Agreement, 0.01–0.20 as None to Slight, 0.21–0.40 as Fair, 0.41–0.60 as Moderate, 0.61–0.80 as Good and 0.81–1.00 as Almost Perfect agreement [16]. Data analysis was performed using IBM SPSS statistic version 20.0 [17]. The variances in grading the toxicity were observed, categories included perfect concordance, one grade and two grade differences.

Toxicity incidence of midpoint and endpoint were analysed in order to further eliminate ‘zero grading’ between the observers and to discriminate whether the HN APRT was able to recognize the toxicities that arose during RT.

Results

A total of twenty three patients were included in this study, with 10 patients receiving RT alone while 13 patients had CCRT. Patient demographics and disease characteristics are summarised in Table 2. The median age was 52 (range 24–75 years). 74% of the patients were male and 82.6% were of Chinese ethnicity. Patients with AJCC 7th Edition Stage I and II received RT alone while patients with Stage III and Iva/Ivb disease received chemoradiotherapy.

A total of 721 entries were recorded independently by ROs and HN APRT for the patients categorized under the evaluated toxicities. Xerostomia, dysgeusia, pharyngolaryngeal pain and dermatitis assessment were evaluated as ‘Good’ agreement level ($\kappa = 0.608–0.640$) between the HN APRT and ROs. ‘Moderate’ agreement was observed for oral pain ($\kappa = 0.578$) and mucositis ($\kappa = 0.576$) assessment. Dysphagia scored an ‘Almost Perfect’ agreement level with $\kappa = 0.834$ (Table 3).

Overall, the HN APRT achieved a high concordance rate of 78.4% with the ROs for the 7 graded toxicities. One grade difference in toxicity assessment between HN APRT and ROs was observed in 21.2% of patients. Two grade differences was only seen in grading of mucositis, where there were 2.9% of patients that were graded differently (Table 4).

Table 5 demonstrated the concordance rates with individual ROs.

### Table 1: Assessment of symptoms of the head and neck radiation induced toxicities.

| Toxicity              | Method in assessing radiation induced toxicities |
|-----------------------|-------------------------------------------------|
| Nutrition             | Weight, Amount of food intake                   |
| Xerostomia            | Subjective degree of dryness and assessment on the stickiness of saliva |
| Mucositis             | Physical examination of the oral cavity, oropharynx region |
| Oral Pain             | The degree of oral pain on scale scoring related to mucositis, inflammation of gums, buccal mucosal (at rest, talking or eating/drinking) |
| Dysgeusia             | Subjective degree of taste alteration or loss of taste |
| Dysphagia             | Ease of swallowing function (smooth, difficulty, unable to swallow, choking) |
| Pharyngolaryngeal Pain| The degree of pain on scale scoring when swallowing, require NGT (with/without analgesic intervention) |
| Dermatitis            | Physical examination of the skin                |
who reviewed NPC patients on their respective clinic day. The HN APRT assessed the NPC patients on the same day as the RO 1 and scored the highest agreement of 92.7%.

Further analysis of the toxicity incidence at midpoint and endpoint of the NPC patients was performed (Table 6). Overall assessment was similar for most of the toxicities, with a high concordance achieved by both observers in identifying ‘grade 3′ toxicities. Minor discrepancy in evaluating xerostomia and dermatitis were observed for the endpoint.

Discussion

RT is the main treatment modality for NPC. Studies have shown that CCRT confers a significant survival benefit for patients with locally advanced disease [2,7]. Most patients undergoing RT for NPC will experience some RT related side effects. These side effects manifest earlier and are increased in frequency and severity for patients receiving CCRT [2,7,18]. In the study by Monk et al. [19], an audit of treatment review clinic showed that overall, 93% HN cases required medical intervention during RT. Weekly treatment reviews are crucial for toxicities such as oral pain, mucositis, dermatitis and dysphagia to be recognized and treated before patients become severely ill [18,19]. This allows patients with ‘Category 1′ (rapidly proliferating) tumour to complete their treatment without interruptions, so that their outcome is not compromised [11].

From the results, there was a significant agreement achieved between the HN APRT and ROs in assessing toxicities in dysphagia, xerostomia, pharyngolaryngeal, dysgeusia and dermatitis with the agreement level of ‘Moderate’ to ‘Almost Perfect’ while there was slight variability in oral pain and mucositis. Oral pain arises as a consequence of development of mucositis, undoubtedly both graded toxicities are inter-related [8]. In the healthcare setting, Kappa statistic above the ‘Moderate’ rating (κ > 0.600) is considered reliable consistency for the inter-rater because it is a more robust measurement and it includes the possibility of agreement occurring by chance [16]. With a high inter-rater assessment and a perfect concordance of 78.4% for grading all toxicities, these results indicate that a properly trained HN APRT can be as competent as ROs in assessing toxicities during HN treatment. A similar quantitative study carried out by Lee et al. [20] validated that the Clinical Specialist Radiation Therapist (CSRT) possessed the clinical competency in assessing and grading side effects for patients receiving breast radiotherapy.

In our department, clinical schedules only allows for the APRT led treatment review clinic to run every Monday whereas the individual ROs weekly clinics were scheduled on Mondays, Thursdays, and Fridays depending on their availability. Indeed, there was a significantly high percentage agreement of 92.7% concordance rate with RO 1 who conducted the review clinic on the same day (Table 4). Subsequently, the clinic day for RO 2 was three days apart, with the concordance rate of

![Fig. 1. A sample of a graded HN Acute toxicity assessment form.](image-url)
due to increased complexity of clinical practices, radiotherapy technicians may need to review a patient’s treatment a week in order for the toxicities to be recognized and escalated to the ROs for medical intervention, leading to improved communication between the RTs and ROs as well as promoting a collaborative approach in managing patients’ overall wellbeing [12, 14, 19, 22].

Patients undergoing HN radiotherapy will typically manifest radiation induced adverse toxicities gradually over the course of treatment. Thus, our current study also assessed the concordance and agreement levels of the RO and HN APRT in toxicity grading over two time point (mid and endpoint) to assess non-zero grade toxicities. The overall concordance and agreement between the HN APRT and ROs in reviewing the HN patients, there is an improved communication between the RTs and ROs as well as promoting a collaborative approach in managing patients’ overall wellbeing [12, 14, 19, 22].

Table 5
Percentage agreement and grade differences between the HN advanced practice radiation therapist and individual radiation oncologist*

| Toxicity               | RO 1 (Monday) | RO 2 (Thursday) | RO 3 (Friday) |
|------------------------|---------------|-----------------|---------------|
|                        | same % | 1 grade difference % | 2 grade difference % | same % | 1 grade difference % | 2 grade difference % | same % | 1 grade difference % | 2 grade difference % |
| Xerostomia             | 94.6  | 5.4   | 0     | 75.0  | 25.0  | 0.0  | 61.9  | 38.1  | 0.0  |
| Oral Pain              | 89.2  | 10.8  | 0     | 73.3  | 26.7  | 0.0  | 63.6  | 36.4  | 0.0  |
| Mucositis              | 89.2  | 10.8  | 0     | 64.5  | 31.1  | 4.0  | 61.9  | 33.3  | 4.8  |
| Dysgeusia              | 89.2  | 10.8  | 0     | 82.2  | 17.7  | 0.0  | 54.5  | 45.5  | 0.0  |
| Dysphagia              | 97.3  | 2.7   | 0     | 88.6  | 11.4  | 0.0  | 76.2  | 3.8   | 0.0  |
| Pharyngolaryngeal Pain| 91.9  | 8.1   | 0     | 70.5  | 29.5  | 0.0  | 57.1  | 42.8  | 0.0  |
| Dermatitis             | 97.3  | 2.7   | 0     | 58.7  | 41.3  | 0.0  | 81.0  | 19.0  | 0.0  |
| Average                | 92.7  | 7.3   | 0     | 73.3  | 26.1  | 0.6  | 65.2  | 31.3  | 0.7  |

* Only entries which were assessed by both RO and APRT were included in this table.

Table 6
Toxicity incidence assessed during midpoint and endpoint of treatment course between the HN advanced practice radiation therapist and individual radiation oncologist*

| Week (Midpoint) | RO | APRT |
|-----------------|----|------|
| Toxicity        | G0 | G1   | G2   | G3   | G0   | G1   | G2   | G3   |
| Xerostomia      | 82.4 | 17.6 |
| Oral Pain       | 47.1 | 47.1 | 5.9  |
| Mucositis       | 17.6 | 52.9 | 29.4 |
| Dysgeusia       | 70.6 | 29.4 |
| Dysphagia       | 58.8 | 23.5 |
| Pharyngolaryngeal Pain | 41.2 | 47.1 | 11.8 |
| Dermatitis      | 29.4 | 58.8 | 5.9  |
| Average         | 76.5 | 23.5 |

|Week (Endpoint) | RO | APRT |
|----------------|----|------|
| Toxicity       | G0 | G1   | G2   | G3   | G0   | G1   | G2   | G3   |
| Xerostomia     | 29.4 | 70.6 |
| Oral Pain      | 11.8 | 52.9 | 35.3 |
| Mucositis      | 23.5 | 64.7 | 11.8 |
| Dysgeusia      | 23.5 | 76.5 |
| Dysphagia      | 17.6 | 64.7 | 17.6 |
| Pharyngolaryngeal Pain | 11.8 | 23.5 | 52.9 | 11.8 |
| Dermatitis     | 5.9  | 70.6 | 23.5 |
| Average        | 5.9  | 94.1 |

* Only entries which were assessed by both RO and APRT were included in this table.

73.3% and followed by reduction to 65.2% of concordance with RO 3 where the consultation was four days apart from the APRT treatment review. Overall, the ‘one grade difference’ was noted to be slightly higher for RO review days on Thursday and Friday. Interestingly, there was an increasing disparity over the week between two assessors which was reflected in the average toxicity grading. This can be explained by the cumulative side effects that occur between Mondays (when assessment was performed by APRT) to Thursday/Friday (when assessment was performed by ROs).

The patients with a ‘two grade difference’ that was observed between the HN APRT and RO 2 and 3 were all undergoing CCRT and the mucositis was likely to be accentuated by chemotherapy as a radiosensitizer [2]. Multiple studies have shown that NPC patients with CCRT potentially have worsening toxicities, therefore resulting in the discrepancy on mucositis occurrence within a few days [2, 7, 21]. This result could suggest that patients on CCRT may require more than just one treatment review a week in order for the toxicities to be recognized early and intervention be initiated. However, in many centres, treatment review is usually performed by the primary ROs, registrars or medical officers (MOs) on a weekly basis. Demand on doctors’ time is increasing due to increased complexity of clinical practices, radiotherapy techniques as well as other competing demands from additional responsibilities in research, education and administration [12].

We propose that a trained APRT may be a viable solution to fill this gap. While the APRT’s role is not to deliver medical treatment or to replace the RO, early accurate recognition of toxicities needing intervention can be escalated to the ROs for medical intervention, leading to improved symptom control, improved quality of life and lesser treatment interruption. Moreover, through a strong collaboration between HN APRT and ROs in reviewing the HN patients, there is an improved communication between the RTs and ROs as well as promoting a collaborative approach in managing patients’ overall wellbeing [12, 14, 19, 22].

There are several limitations for this study. Ideally, all treatment reviews should be performed on the same day to improve validity of comparison. It was decided to take a pragmatic approach so as not interrupt routine clinical practice. Secondly, there was some missing data as the ROs may not have the reviewed the patients timely on a
weekly basis due to other commitments. This is precisely the argument to have a trained APRT to fill this gap left by the busy RO. Thirdly, the study number is relatively small and commitment from both reviewers was a limiting factor to extend the duration of the study. Fourthly, ROs’ toxicities were written in chart documentation had to be translated to the CTCAE form for comparison. This could result in a possibility of translational or interpretational errors. In order to mitigate this, any uncertainties in RO’s grading were verified with the RO making the entry. Finally, this study was limited to a specific subset of patients with NPC only. While it is difficult to confidently conclude that the result of this study is generalizable to all HN cancers, we believe that the ability of an APRT to assess toxicities is transferable to other HN subsites.

Conclusions

This study demonstrated a high concordance between APRT and ROs in weekly assessment of toxicities for patients on treatment for NPC. These results support the continuing involvement of the HN APRT in weekly assessments for NPC patients. With a well-structured training program and competency based accreditation, APRT can provide this value added service in radiotherapy departments. This allows early identification of patients needing medical attention thus minimising treatment interruptions. It also allows RO time to be utilised for other responsibilities. Moving forward, our department is keen to explore HN APRT led treatment toxicity assessment beyond NPC to other HN subsites.

Funding

Melvin L.K. Chua is supported by the National Medical Research Council Singapore Clinician Scientist Award (NMRC/CSA-INV/0027/2018), National Research Foundation Proton Competitive Research Program (NRF-CRP17-2017-05), Ministry of Education Tier 3 Academic Research Fund (MOE2016-T3-1-004), the Duke-NUS Oncology Academic Program Goh Foundation Proton Research Programme, NCCS Cancer Fund, and the Kua Hong Pak Head and Neck Cancer Research Programme.

Declaration of Competing Interest

The authors of this article report no conflict of interest. Disclosure of potential conflicts of interest: Melvin L.K. Chua reports personal fees from Astellas, Janssen, Bayer, Pfizer, MSD, personal fees and non-financial support from AstraZeneca, personal fees and grants from Ferring, personal fees and non-financial support from Varian, non-financial support from Decipher Biosciences, non-financial support from MedLever, and consults for immunoSCAPE Inc., outside the submitted work.

References

[1] Mankowski NL, Bordoni B. Anatomy, Head and Neck, Nasopharynx. StatPearls Publishing, Treasure Island (FL); 2021. p. 27.

[2] Wee J, Tan EH, Tai BC, Wong HB, Leong SS, Tan T, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. Clinical Trial 2005;23(27):6730–8.

[3] Singapore Cancer Registry Annual Report 2018. National Registry of Diseases Office Health Promotion Board: Singapore; 2021.

[4] Chua MLK, Wee JTS, Hui EP, Chan ATC. Nasopharyngeal carcinoma. The Lancet 2016;387(10022):1012–24.

[5] Salihiniya H, et al. Nasopharyngeal cancer in the world: epidemiology, incidence, mortality and risk factors. World Cancer Res J 2018;5(1):1046.

[6] Lee N, Harris J, Garden AS, Straube W, Glisson B, Xia P, et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol 2009;27(22):3684–90.

[7] Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. J Clin Oncol 1998;16(4):1310–7.

[8] Bonomi M, et al. The role of inflammation in head and neck cancer. Adv Exp Med Biol 2014;816:107–27.

[9] Kwong DLY, Sham JST, Chua DTY, Choy DTY, Au GKH, Wu PM. The effect of interruptions and prolonged treatment time in radiotherapy for nasopharyngeal carcinoma. Int J Radiation Oncol Biol Phys 2014;816:107–16.

[10] Thomas K, Martin T, Gao A, Ahn C, Wilhelm H, Schwartz DL. Interruptions of head and neck radiotherapy across insured and indigent patient populations. J Oncol Pract 2017;13(4):e119–28.

[11] The timely delivery of radical radiotherapy: guidelines for the management of unscheduled treatment interruptions. Royal College of Radiologists; 2019. p. 39.

[12] Wong DMM, Sin SY, Lim LH, Pusul Senthia BMA, Lin J, Melina K, et al. The implementation of an advanced practice radiation therapy (APRT) program in Singapore. Tech Innov Support Radiation Oncol 2021;17:63–70.

[13] Lean L. The role of the ‘on treatment’ review radiographer: what are the requirements? J Radiother Pract 2008;7:113–31.

[14] Job M, Holt T, Bernard A. Reducing radiotherapy waiting times for palliative patients: The role of the Advanced Practice Radiation Therapist. J Med Radiat Sci 2017;64(4):274–80.

[15] Shi J, Cox J, Ayteo J, Loh Y, Cheung WL, Back M. Clinician and therapist perceptions on radiation therapist-led treatment reviews in radiation oncology practice. Radiother Oncol 2008;89(3):361–7.

[16] McHugh ML. Interrater reliability: the kappa statistic. Biochemia Medica 2012;22(3):276–82.

[17] IBM Corp. IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp.; 2019.

[18] Tolentino Ed, et al. Oral adverse effects of head and neck radiotherapy: literature review and suggestion of a clinical oral care guideline for irradiated patients. J Appl Oral Sci 2011;19(5):448–454.

[19] Monk CM, Wrightson SJ, Smith TN. An exploration of the feasibility of radiation therapist participation in treatment reviews. J Med Radiat Sci 2013;60(3):100–107.

[20] Lee G, et al. Radiotherapy treatment review: A prospective evaluation of concordance between clinical specialist radiation therapist and radiation oncologist in patient assessments. J Med Imag Radiation Sci 2012;43(1):6–10.

[21] Du Cheng-run, Ying Hong-mei, Kong Fang-fang, Zhai Rui-ping, Hu Chao-su. Concurrent chemoradiotherapy was associated with a higher severe late toxicity rate in nasopharyngeal carcinoma patients compared with radiotherapy alone: a meta-analysis based on randomized controlled trials. Radiation Oncol 2015;10(1). https://doi.org/10.1186/s13014-015-0377-9.

[22] Colyer H. The role of the radiotherapy treatment review radiographer. Radiography 2000;6(4):253–60.

[23] Zhang Sheng, Liang Fei, Tannock Ian. Use and misuse of common terminology criteria for adverse events in cancer clinical trials. BMC Cancer 2016;16(1). https://doi.org/10.1186/s12885-016-2408-9.